Feb 12 (Reuters) - Gilead Sciences on Monday said it will acquire CymaBay Therapeutics for $4.3 billion, to expand its portfolio of liver disease drugs.
Shares of CymaBay were halted ahead of the announcement in premarket hours. (Reporting by Bhanvi Satija in Bengaluru; Editing by Krishna Chandra Eluri)
There's a much more popular AI stock on Capitol Hill than the leading AI chip maker.
Nancy Pelosi's husband Paul Pelosi uses an investing strategy that lowers upfront costs.
A month after a higher state minimum wage for fast-food workers went into effect, consumers picking up burgers and burritos at chains in the Golden State grapple with prices rising at a faster clip than in other states.
If you have inherited retirement assets, have a Roth 401(k) or want to give retirement money to charity, you may be impacted by tweaks to this year’s rules for RMDs.
Whether or not these stocks hit analysts' price targets, they all should be attractive to investors seeking great income and solid growth.
Here's what could happen next to Alphabet shares.
In addition to economic and earnings news, inflation and geopolitical worries will have roles to play.
The $50 million purchase could turn into Nvidia's biggest investment.
“When she died, we were told by her attorney that we were responsible for the taxes and property insurance during the time when the life tennant lives in the home.”
The number probably isn't anywhere near what you think it is.